Back to library
Research ChemicalResearch

MENT (7-alpha-methyl-19-nortestosterone)

MEN(T)

Research profile · How we handle evidence

Category

Research Chemical

Compound type

Phase / Status

Research

Never approved, research only

Standard Dose

10-50mg daily

As directed

Half-life

Unknown

Plasma elimination

Route(s)

OR / IN / TO

Oral, Injectable or Topical

Research Stage

Status Unknown

Research phase not specified; exercise appropriate caution.

Overview

MENT is often discussed as an androgen with reduced DHT conversion compared with some other compounds. The reason it comes up in research and niche circles is the potential for a stronger androgen signal with a different DHT profile. Safety and long-term risk data are limited, and androgenic compounds can carry meaningful cardiovascular and other health risks. If someone is considering anything like this, talk with a clinician and use thyroid/cardiac-style monitoring when appropriate.

Plain-language summary

MENT is often discussed as an androgen with reduced DHT conversion compared with some other compounds. The reason it comes up in research and niche circles is the potential for a stronger androgen signal with a different DHT profile. Safety and long-term risk data are limited, and androgenic compounds can carry meaningful cardiovascular and other health risks. If someone is considering anything like this, talk with a clinician and use thyroid/cardiac-style monitoring when appropriate.

Administration Routes

  • Oral
  • Injectable
  • Topical

Also known as

TrestoloneTrestMENT7-alpha-MENT7alpha-MNTMENT acetateTrest Ace

Mechanisms

1

Synthetic androgen resistant to 5-AR

Detailed mechanism

MENT (trestolone) is a 7-alpha-methyl-19-nortestosterone derivative that binds androgen receptors with high affinity and resists conversion to dihydrotestosterone (DHT) via 5-alpha-reductase, which distinguishes its tissue activity profile from testosterone. It also exhibits progestogenic activity through progesterone receptor binding, contributing to its suppression of the hypothalamic-pituitary-gonadal (HPG) axis and endogenous testosterone production. Because it cannot be converted to DHT, androgenic effects in tissues such as the prostate and scalp may differ relative to testosterone, though meaningful androgenic and cardiovascular risks remain.

Safety

Side effects

  • Liver toxicity
  • Cardiovascular stress
  • Unknown long-term effects

Reported benefits

  • Extreme androgenic activity
  • No DHT conversion
  • Muscle building

Safety profile

Consult medical professional before use

Clinical trials

See research status

Structure

View 3D structure

Verified structure

MENT (7-alpha-methyl-19-nortestosterone)

Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.

Verified via PubChemMatched by casNumber
Source: PubChemLookup: 3764-87-2InChIKey YSGQGNQWBLYHPE-UHFFFAOYSA-N
Chemical Formula
C19H28O2
Molecular Weight
288.4 g/mol
CAS Number
3764-87-2
InChIKey
YSGQGNQWBLYHPE-UHFFFAOYSA-N

Stack Context

No stack data available.

References

  1. 1

    Trestolone (MENT, 7-alpha-methyl-19-nortestosterone) - PubChem Compound Summary (NLM)

    View source
  2. 2

    Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review (PMC)

    2021

    View source
  3. 3

    7 alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy (Ann Med)

    1995

    View source

This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.

Research-driven insights.Evidence-based decisions.